Cargando…

IGFBP7 and left ventricular mass regression: a sub‐analysis of the EMPA‐HEART CardioLink‐6 randomized clinical trial

AIMS: Given recent suggestions that serum levels of insulin‐like growth factor‐binding protein 7 (IGFBP7) may identify patients who derive greater cardiorenal benefits from treatment with sodium‐glucose transport 2 inhibitors (SGLT2i), this exploratory sub‐analysis of the EMPA‐HEART CardioLink‐6 ran...

Descripción completa

Detalles Bibliográficos
Autores principales:	Puar, Pankaj, Mistry, Nikhil, Connelly, Kim A., Yan, Andrew T., Quan, Adrian, Teoh, Hwee, Pan, Yi, Verma, Raj, Hess, David A., Verma, Subodh, Mazer, C. David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Short Communications
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10192263/ https://www.ncbi.nlm.nih.gov/pubmed/37038626 http://dx.doi.org/10.1002/ehf2.14335

Ejemplares similares

Effect of empagliflozin on cardiac remodelling in South Asian and non-South Asian individuals: insights from the EMPA-HEART CardioLink-6 randomised clinical trial
por: Barbour, William, et al.
Publicado: (2023)

Does empagliflozin modulate the autonomic nervous system among individuals with type 2 diabetes and coronary artery disease? The EMPA-HEART CardioLink-6 Holter analysis
por: Garg, Vinay, et al.
Publicado: (2020)

Impact of diabetes duration on left ventricular mass regression with empagliflozin
por: Moroney, Michael, et al.
Publicado: (2023)

Randomised trial of mitral valve repair with leaflet resection versus leaflet preservation on functional mitral stenosis (The CAMRA CardioLink-2 Trial)
por: Chan, Vincent, et al.
Publicado: (2017)

Left ventricular mass predicts cardiac reverse remodelling in patients treated with empagliflozin
por: Puar, Pankaj, et al.
Publicado: (2023)

SGLT2 inhibitors and cardiac remodelling: a systematic review and meta‐analysis of randomized cardiac magnetic resonance imaging trials
por: Dhingra, Nitish K., et al.
Publicado: (2021)

Baseline neutrophil‐to‐lymphocyte ratio and efficacy of SGLT2 inhibition with empagliflozin on cardiac remodelling
por: Verma, Raj, et al.
Publicado: (2023)

Axillary versus innominate artery cannulation for antegrade cerebral perfusion in aortic surgery: design of the Aortic Surgery Cerebral Protection Evaluation (ACE) CardioLink-3 randomised trial
por: Garg, Vinay, et al.
Publicado: (2017)

Association between uric acid levels and cardio‐renal outcomes and death in patients with type 2 diabetes: A subanalysis of EMPA‐REG OUTCOME
por: Verma, Subodh, et al.
Publicado: (2020)

The Impact of Statins on Postdischarge Atrial Fibrillation After Cardiac Surgery: Secondary Analysis from a Randomized Trial
por: Hibino, Makoto, et al.
Publicado: (2022)

Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial
por: Verma, Subodh, et al.
Publicado: (2018)

Stage‐based approach to predict left ventricular reverse remodeling after mitral repair
por: Hibino, Makoto, et al.
Publicado: (2022)

Impact of polyvascular disease with and without co‐existent kidney dysfunction on cardiovascular outcomes in diabetes: A post hoc analysis of EMPA‐REG OUTCOME
por: Verma, Subodh, et al.
Publicado: (2021)

Generalizability of REDUCE-IT eligibility criteria in a large diabetes cardiovascular outcomes trial: A post hoc subgroup analysis of EMPA-REG outcome: Analysis of EMPA-REG OUTCOME using REDUCE-IT criteria
por: Verma, Subodh, et al.
Publicado: (2023)

Empagliflozin reduces the risk of mortality and hospitalization for heart failure across Thrombolysis In Myocardial Infarction Risk Score for Heart Failure in Diabetes categories: Post hoc analysis of the EMPA‐REG OUTCOME trial
por: Verma, Subodh, et al.
Publicado: (2020)

Cardio/Kidney Composite End Points: A Post Hoc Analysis of the EMPA‐REG OUTCOME Trial
por: Ferreira, João Pedro, et al.
Publicado: (2021)

Time to cardiovascular benefits of empagliflozin: a post hoc observation from the EMPA‐REG OUTCOME trial
por: Verma, Subodh, et al.
Publicado: (2021)

Empa's New Clothes: The Untold Story of the Empa-Reg Outcome Trial
por: Alzaid, Aus
Publicado: (2017)

Role of Endothelium in Doxorubicin-Induced Cardiomyopathy
por: Luu, Albert Z., et al.
Publicado: (2018)

Circulating Pro-Vascular Progenitor Cell Depletion During Type 2 Diabetes: Translational Insights Into the Prevention of Ischemic Complications in Diabetes
por: Terenzi, Daniella C., et al.
Publicado: (2018)

Endothelial cell control of thrombosis
por: Yau, Jonathan W., et al.
Publicado: (2015)

Canagliflozin Improves the Recovery of Blood Flow in an Experimental Model of Severe Limb Ischemia
por: Sherman, Stephen E., et al.
Publicado: (2018)

Metabolic syndrome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a post hoc analyses of the EMPA-REG OUTCOME trial
por: Ferreira, João Pedro, et al.
Publicado: (2020)

Recent cannabis use and myocardial infarction in young adults: a cross-sectional study
por: Ladha, Karim S., et al.
Publicado: (2021)

Usage récent de cannabis et infarctus du myocarde chez de jeunes adultes: étude transversale
por: Ladha, Karim S., et al.
Publicado: (2022)

Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: Findings from the EMPA‐REG OUTCOME trial
por: Vaduganathan, Muthiah, et al.
Publicado: (2021)

Vascular Risk Reduction in Obesity through Reduced Granulocyte Burden and Improved Angiogenic Monocyte Content following Bariatric Surgery
por: Hess, David A., et al.
Publicado: (2020)

Subclinical Valve Thrombosis in Sutureless Bioprosthetic Valves
por: Yanagawa, Bobby, et al.
Publicado: (2017)

Predictors of mitral valve haemodynamics after mitral valve repair for degenerative mitral regurgitation
por: Rumman, Rawan K, et al.
Publicado: (2023)

Association study of IGFBP1 and IGFBP3 polymorphisms with hypertension and cardio-cerebral vascular diseases in a Chinese Han population
por: Fang, Zhengmei, et al.
Publicado: (2017)

NIMS and Empa announce STAM collaboration
por: Yoshida, Toyonobu, et al.
Publicado: (2014)

Isolation and characterization of circulating pro-vascular progenitor cell subsets from human whole blood samples
por: Terenzi, Daniella C., et al.
Publicado: (2021)

The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study
por: Herrington, William G, et al.
Publicado: (2018)

The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study
por: Herrington, William G, et al.
Publicado: (2019)

Bladder cancer in the EMPA-REG OUTCOME trial
por: Kohler, Sven, et al.
Publicado: (2017)

Cardiovascular outcomes and LDL-cholesterol levels in EMPA-REG OUTCOME(®)
por: Langslet, Gisle, et al.
Publicado: (2020)

Gel shift analysis of the empA promoter region in Vibrio anguillarum
por: Denkin, Steven M, et al.
Publicado: (2004)

EMPAS: Electron Microscopy Screening for Endogenous Protein Architectures
por: Kim, Gijeong, et al.
Publicado: (2020)

Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial
Publicado: (2022)

Loss of endothelial cell-specific autophagy-related protein 7 exacerbates doxorubicin-induced cardiotoxicity
por: Luu, Albert Z., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_psu63gjqi7p28cf068fv97uua9